Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7459

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: TAK-881, HYQVIA; Biological
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more

Conditions: Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Interventions: Exaluren; Drug
Lead sponsor: Eloxx Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 4 more

Conditions: Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma
Interventions: NXP900; Drug
Lead sponsor: Nuvectis Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Standard of care; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 180
States / cities: Buena Park, California • Burbank, California • Costa Mesa, California + 144 more

Conditions: Newly Diagnosed and Recurrent Glioblastoma
Interventions: [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 36,814 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more

Conditions: Lymphoma, B-Cell
Interventions: obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 38
States / cities: Birmingham, Alabama • Encinitas, California • Aurora, Colorado + 34 more

Conditions: Melanoma (Skin)
Interventions: interferon alfa-2b, observation; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2026
U.S. locations: 511
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more

Conditions: Relapsed Refractory Multiple Myeloma
Interventions: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 48
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 93
States / cities: Fresno, California • Martinez, California • Roseville, California + 70 more

Clinical trials in Denver, Colorado

Filter and sort this location

Live official records

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy